Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 19;220(2):266-269.
doi: 10.1093/infdis/jiz096.

Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV

Julia A Aepfelbacher  1 , Julia Balmaceda  1 , Julia Purdy  2 , Aviva Mattingly  1 , Kirsten Zambell  3 , Karyn Hawkins  4 , Cheryl Chairez  1 , Kara Anne Curl  1 , Nicola Dee  1 , Colleen Hadigan  1
Affiliations
Clinical Trial

Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV

Julia A Aepfelbacher et al. J Infect Dis. .

Abstract

Little is known about the effects of lifelong human immunodeficiency virus (HIV) or antiretroviral therapy on hepatic steatosis and fibrosis. Using transient elastography, we evaluated 46 young adults with lifelong HIV and 20 matched HIV-negative controls. Steatosis was present in 33% of persons with HIV and only 10% of controls (P = .04). Hepatic fibrosis scores were not elevated and did not differ between groups. Metabolic parameters, particularly increased waist circumference, and not HIV-specific factors, were significantly associated with steatosis. While this finding should be examined in larger cohorts, modifiable metabolic disturbances may be important targets to optimize liver health in this population.

Trial registration: ClinicalTrials.gov NCT01656564.

Keywords: AIDS; HIV; hepatic steatosis; nonalcoholic fatty liver disease; young adults.

PubMed Disclaimer

References

    1. Dam-Larsen S, Franzmann M, Andersen IB, et al. . Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53:750–5. - PMC - PubMed
    1. Maurice JB, Patel A, Scott AJ, Patel K, Thursz M, Lemoine M. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 2017; 31:1621–32. - PubMed
    1. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017; 377:2063–72. - PubMed
    1. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62:1148–55. - PubMed
    1. Perazzo H, Cardoso SW, Yanavich C, et al. . Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc 2018; 21:e25201. - PMC - PubMed

Publication types

Associated data